Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 311 participants.
Also called NCT01392677
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 311 participants
- Sponsor
- Registry
-
NCT01392677
-
- Other papers using this trial's data
- Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Canada, Czechia, Germany, Poland, Slovakia, Spain
- Registry status
- Completed
Technical summary
Registry record NCT01392677. Randomized; quadruple masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2013-01 (actual). Results posted on 2013-12-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
- Condition
- Type 2 Diabetes Mellitus
- Condition
- High HbA1c Level
- Condition
- Inadequate Glycaemic Control
- Intervention (Drug)
- dapagliflozin
- Intervention (Drug)
- placebo
- Lead sponsor
- AstraZeneca
- Collaborator
- Bristol-Myers Squibb
Record details
- Record id
cardio:ct-nct01392677- Content hash
0154aeac30837cc9939f62ae6cdbed7d6335c054499b69941cf94fcdff1b8d2d